Sargas et al. (2021). Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: The PETHEMA NGS-AML project. Haematologica, 106(12), (3079-3089). doi:10.3324/haematol.2020.263806
Meggendorfer et al. (2018). IDH1R132, IDH2R140 and IDH2R172 in AML: Different genetic landscapes correlate with outcome and may influence targeted treatment strategies. Leukemia, 32(5), 1249-1253. doi:10.1038/s41375-018-0026-z
Hagiya et al. (2019). Bone marrow features in patients with acute myeloid leukemia treated with novel targeted isocitrate dehydrogenase 1/2 inhibitors. World Journal of Oncology, 10(6), 226-230. doi:10.14740/wjon1231
Kansal et al. (2016). Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biology and Medicine, 13(1), 41-54. doi:10.28092/j.issn.2095-3941.2016.0001